Guido Marcucci, MD [Chair] ('13)
Hartmut Dohner, MD [Vice Chair] (’13)
Michael W. Becker, MD ('14)
Christopher R. Cogle, MD ('14)
Lucy Godley, MD, PhD ('15)
Jiong Hu, MD (’13)
Jaroslaw P. Maciejewski, PhD, MD, FACP ('15)
Ravi Majeti, MD, PhD ('14)
Vivian Oehler, MD ('13)
Radek C. Skoda, MD ('14)
The Scientific Committee on Myeloid Neoplasia is focused on the biology and treatment of myeloid malignancies. Underlying the Committee’s emphasis on the pathobiology of malignancies involving the myeloid lineage is the premise that clarifying the basic mechanisms of myeloid neoplasia will lead to more effective and less toxic treatments. There is an increasing awareness of the heterogeneity of myeloid malignancies demanding rational and adapted therapies. Pediatric and adult as well as acute and chronic myeloid malignancies are areas of interest.
Biological/mechanistic areas of interest
Aberrant genetic and epigenetic changes contribute to myeloid leukemogenesis. Many of these molecular abnormalities affect myeloid differentiation, proliferation, and senescent (apoptotic) pathways. The Committee emphasizes topics that address the role of genes and pathways critical for myeloid development that have been implicated in the pathobiology of myeloid malignancies. The development of the next-generation, high-throughput DNA sequencing and other technologies including epigenomic, proteinomic, metabolomic, and bioinformatic methods are expected to be used routinely in the classification and prognosis and guide therapy of myeloid malignancies. To integrate data from these new techniques with those from clinical, epidemiological, conventional (morphologic, immunophenotypic, cytogenetic) laboratory data into a treatment plan will remain the major challenge for the next several years.
Clinical areas of interest
The management of the BCR-ABL-positive chronic myeloid leukemia (CML) is the paradigm for the treatment of myeloid malignancies. Several tyrosine kinase inhibitors have been developed and tested in CML and other hematological malignancies. New effective drugs will likely to be discovered for different types of myeloid malignancy targets. Defining drug efficacy and relevance for specific genotypes using traditional Phase I, II, III studies or alternative methods are of clinical interest.
The Committee focuses on all aspects of research that have an impact on our understanding of the cellular mechanisms that lead to myeloid malignancies. Specific examples are:
- How next-generation sequencing defines new genes and mutations critical for myeloid development
- How we translate new scientific knowledge into clinical relevance
- New techniques that can be applied to the study of myeloid disorders: microarrays; next-generation sequencing; epigenetic, proteinomic, and metabolomic methodologies
Emerging areas of interest
Areas that are becoming increasingly important in the field of myeloid biology are:
- The role that next-generation sequencing (NGS) will have in potentially defining all of the genes mutated in myeloid diseases
- How large amounts of data generated by NGS are integrated to produce new nosologic classification of myeloid malignancies and personalized (risk-adapted) therapies
- Inherited predisposition to myeloid disorders
Potential overlap and resolution with other scientific committees
- Blood Disorders in Childhood: Because children develop myeloid malignancies, there is an inherent overlap with this committee. The issue of “age-oriented vs. “topic-oriented” can be resolved during the elaboration of annual topics.
- Hematopathology and Clinical Laboratory Hematology: Because the clinical diagnosis of myeloid disorders is made by hematopathologists, there is an inherent overlap with this committee.
- Hematopoiesis: Our Committee focuses on the malignant aspects of hematopoiesis and is inherently informed by an understanding of normal hematopoiesis. There is a natural bridge from the normal pathways to the malignant and, therefore, from this committee to ours.
- Myeloid Biology: Likewise for this committee, normal hematopoiesis informs an understanding of malignant processes.
Appropriate sessions at the ASH annual meeting
Our Committee would benefit from any presentation that addresses genes or pathways associated with the development, diagnosis, prognosis, and/or clinical relevance of myeloid malignancies, both acute and chronic. Major advances in understanding of cellular events that are associated with myeloid malignancies or definition of new potential therapeutic targets would be areas of interest to this Committee.
back to top